| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Advancing the Management of CH, MDS, and AML From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference
|
Carraway, Hetty E.
|
|
|
25 |
8 |
p. 583-589
|
article
|
| 2 |
Analyzing Two Decades of Leukemia Mortality in the U.S. (1999-2020)
|
Aziz, Nouman
|
|
|
25 |
8 |
p. e553-e562
|
article
|
| 3 |
Chemotherapy Trends in Acute Myeloid Leukemia: 2004 to 2020
|
Ravindra, Aditya
|
|
|
25 |
8 |
p. e541-e552
|
article
|
| 4 |
Clinical Outcomes for Multiple Myeloma Patients With Prior Exposure to a Combination of a Proteasome Inhibitor and an Immunomodulatory Agent in Alberta, Canada
|
Jimenez-Zepeda, Victor H.
|
|
|
25 |
8 |
p. e604-e611.e1
|
article
|
| 5 |
Comparison of Real-World Outcomes in Patients With Follicular Lymphoma Treated With BR Versus RCHOP-Like Regimens
|
Baron, Kelsey
|
|
|
25 |
8 |
p. e591-e599.e7
|
article
|
| 6 |
Editorial Board
|
|
|
|
25 |
8 |
p. A1-A2
|
article
|
| 7 |
Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR Trial
|
Weisel, Katja
|
|
|
25 |
8 |
p. 590-605
|
article
|
| 8 |
SOHO State of the Art Updates and Next Questions | Atypical Chronic Myeloid Leukemia: Pathogenesis, Diagnostic Challenges and Therapeutic Strategies
|
Costa, Alessandro
|
|
|
25 |
8 |
p. 558-570
|
article
|
| 9 |
SOHO State of the Art Updates and Next Questions. Atypical Chronic Myeloid Leukemia: Pathogenesis, Diagnostic Challenges, and Therapeutic Strategies
|
Costa, Alessandro
|
|
|
25 |
8 |
p. 571-582
|
article
|
| 10 |
SOHO State of the Art Updates and Next Questions | Latest Advances in the Management of Primary Mediastinal B-Cell Lymphoma
|
Lap, Coen J.
|
|
|
25 |
8 |
p. 543-557
|
article
|
| 11 |
Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at 2 Institutes
|
Varga, Cindy
|
|
|
25 |
8 |
p. e563-e569
|
article
|
| 12 |
Survival, Years of Life Lost and Attrition Rates in Multiple Myeloma Patients in France
|
Perrot, Aurore
|
|
|
25 |
8 |
p. 606-614.e1
|
article
|
| 13 |
Table of Contents
|
|
|
|
25 |
8 |
p. A3-A5
|
article
|
| 14 |
The Impact of Sponsors on Development of Clinical Research in Multiple Myeloma and AL Amyloidosis: An In-Depth Analysis
|
Zayad, Anas
|
|
|
25 |
8 |
p. e600-e603
|
article
|
| 15 |
Treatment Patterns, Efficacy, and Tolerability of Belantamab Mafodotin in Patients With Relapsed and/or Refractory Multiple Myeloma: A Real-World Analysis
|
Patel, Mihir N.
|
|
|
25 |
8 |
p. e570-e579.e4
|
article
|
| 16 |
Unusually Indolent CML: Absence of Complete Cytogenetic Response after 10 Years of Tyrosine Kinase Inhibitor Therapy
|
Shen, Qiudan
|
|
|
25 |
8 |
p. e580-e590
|
article
|
Journal description